Citius Pharmaceuticals Inc

CTXRNASDAQ · USD
0.53USD0.00 (-1.41%)
325

Citius Pharmaceuticals Inc (CTXR) Option Chain

Read more

Tracking the CTXR option chain helps you see every strike and expiry on Citius Pharmaceuticals Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CTXR options activity at a glance. Use our scanner to monitor the CTXR option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CTXR stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CTXR options are being actively traded, and where they are not.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
100.0053800.050.00—0.052.50+362.961.702.101.97-0.07080.00
100.00000.750.00—0.755.00+825.933.904.904.47-0.07000.00
100.00000.750.00—0.757.50+1288.896.407.406.97-0.07000.00

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank63.49% Moderate
  • Market cap (M$)14
  • 52 weeks high-65.58%
  • 52 weeks low43.24%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$4.00
    654.72% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-12-22
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.11
  • EPS growth next 5 years41.69%

As of Nov 16, 2026